AMP protein kinase agonist (Biovitrum)

N/A

Report date: 2025/03/17 20:00:36
NME

Base Information

Drug NameAMP protein kinase agonist (Biovitrum)
Drug Alias NameAMP protein kinase agonist (Arexis)type 2 diabetes therapy (Arexis)type 2 diabetes therapy (Biovitrum)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAMP-activated protein kinases activators
TargetsAMP-activated protein kinases
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArexis AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArexis AB
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A